Xilio Therapeutics, Inc.’s Post

Discover how integrating advanced preclinical solutions can revolutionize target and lead selection in bispecific antibody development. Our latest white paper delves into the strategies that streamline BsAb creation, enhancing precision and efficacy in oncology. Learn from a real-world case study on HX009 and explore how these integrated approaches expedite the path from preclinical assessment to FDA approval. Download the white paper now! ➡️ https://hubs.la/Q02NYHWS0 #OncologyResearch #DrugDevelopment #BispecificAntibodies #BsAb

Biosimilars news is heating up! This week's top stories: interchangeability updates, new approvals, and overcoming barriers to biosimilars in oncology. Click the link below to watch the video of the top 5 articles of the week to learn more about these and other biosimilar advancements! https://lnkd.in/eFKnXkwQ

This exciting session explores topics such as antibody-based checkpoint agonists, mitigating toxicity for T-cell engagers, and macrophage reprogramming techniques, in oncology and inflammation with companies including AltruBio Inc., GenScript, OncoResponse, Sanofi, and more.    Make sure to join Refeyn for this content packed session on Day 1 in Room 6C! #festivalofbiologicsUS

Regor Enters into a Definitive Purchase Agreement for Genentech to Acquire Regor's Portfolio of next-generation CDK inhibitors for the Treatment of Breast Cancer incl. $850m upfront payment https://lnkd.in/e_9ZpuyK Regor Therapeutics Group Genentech Roche Xiayang Qiu > More Transatlantic life science business news at [LSUS] Life-Sciences-USA.com > More European life science business news at [LSE] Life-Sciences-Europe.com > More Asian life science business news at [LSA] Life-Sciences-USA.com -

TuMinimize™, our precision dosing software for oncology, ensures every cancer patient receives the right dose at the right time. Tailored for biologics like bevacizumab, pembrolizumab, and atezolizumab, it is designed to maximize efficacy and minimize side effects. Learn more and book a demo: https://lnkd.in/eZB_YbXz #TuMinimize #OncologyCare #PrecisionMedicine #Baysient #TherapeuticDrugMonitoring

Paper out from Arvinas on pre-clinical characterization of Vepdegestrant (ARV-471). Vepdegestrant was granted Fast Track status by the FDA earlier this year, and is currently being assessed in Phase 3 as a monotherapy and combination therapy with Palbociclib (CDK4/6 inhibitor, Pfizer) in the VERITAC-2 and -3 trials, respectively. The pre-clinical data looks highly promising, with tumour shrinkage in in vivo models when combined with Palbociclib. The paper also contains very thorough mechanistic analysis, demonstrating on-mechanism action and high specificity across the proteome. Paper here: https://lnkd.in/erJEptDC #PROTAC #TPD #Oncology 

Thrilled to witness yet another antibody-drug-conjugate (ADC) deal completed in 2023! ADCs are a great example of a technology that went through challenges and an extended gestation period but has emerged as a major player in oncology and is making a substantial difference for patients. #ADC #HealthcareInnovation #PatientCare #Biotech #Oncology

Check out this webinar done in partnership with BioPharmaDive!

As part of our Domainex med chem forum I had the pleasure to author our latest blog on a really interesting structure based drug design story published by Tango Therapeutics describing the development of a PRMT5 inhibitor for the treatment on MTAP-null cancers. Please have a read and I encourage you to read the paper too! #medicinalchemistry #medchem #drugdiscovery #sbdd

Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update. We currently have two ongoing clinical trials addressing patients with unmet medical needs. ACESOT-1051, our next-generation WEE1 inhibitor targeting solid tumors with specific genetic markers. Early results show no adverse effects in the first cohort. Concurrently, we are progressing with the ABOYA-119 trial for our macrocyclic ATR inhibitor, ATRN-119, furthering our dedication to precision oncology. Aprea Therapeutics has $28.7 million in cash and cash equivalents as of June 30, 2024, with a cash runway extended into Q4 2025. Learn more: https://bit.ly/3WTZgip #InvestorRelations #IR #CancerResearch